11 November 2013: 5-year results of the TARGIT-A trial were published in the The Lancet  


  • When TARGIT is given with lumpectomy, the 5-year local recurrence of breast cancer is similar to EBRT
  • When TARGIT is given as a second procedure, the difference in local recurrence between TARGIT and EBRT was more than 2.5%
  • Breast cancer mortality with TARGIT were similar to EBRT
  • Mortality from other causes  was significantly lower with TARGIT due to fewer deaths from  cardiovascular causes and other cancers.
  • The results remain stable with longer follow up.

Click here to access